Having trouble accessing articles? Reset your cache.

Microplasmin: Phase III data

In the double-blind, international Phase III TG-MV-007 trial in 326 patients, a single 125 µg intravitreal injection of microplasmin met the primary endpoint of significantly increasing the proportion of patients achieving non-surgical resolution

Read the full 334 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE